Title: Defending Antiviral Cationic Amphiphilic Drugs That May Cause Drug-Induced Phospholipidosis.
Authors: Lane, Thomas R; Ekins, Sean
Published In J Chem Inf Model, (2021 09 27)
Abstract: A recent publication in Science has proposed that cationic amphiphilic drugs repurposed for COVID-19 typically use phosholipidosis as their antiviral mechanism of action in cells but will have no in vivo efficacy. On the contrary, our viewpoint, supported by additional experimental data for similar cationic amphiphilic drugs, indicates that many of these molecules have both in vitro and in vivo efficacy with no reported phospholipidosis, and therefore, this class of compounds should not be avoided but further explored, as we continue the search for broad spectrum antivirals.
PubMed ID:
34516123
MeSH Terms: Antiviral Agents/toxicity; COVID-19*; Humans; Lipidoses*/drug therapy; Pharmaceutical Preparations*; Phospholipids; SARS-CoV-2